206
Participants
Start Date
March 12, 2014
Primary Completion Date
December 10, 2021
Study Completion Date
December 10, 2021
Dabrafenib
A 150 mg twice daily capsule administered orally on a continuous basis.
Trametinib
A 2 mg once daily tablet administered orally on a continuous basis.
Novartis Investigative Site, Vienna
Novartis Investigative Site, Jette
Novartis Investigative Site, Copenhagen
Novartis Investigative Site, Linz
Novartis Investigative Site, Salzburg
Novartis Investigative Site, Innsbruck
Novartis Investigative Site, New York
Novartis Investigative Site, Berlin
Novartis Investigative Site, Milan
Novartis Investigative Site, Milan
Novartis Investigative Site, Milan
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Bethesda
Novartis Investigative Site, Madrid
Novartis Investigative Site, Toulouse
Novartis Investigative Site, Bordeaux
Novartis Investigative Site, Nashville
Novartis Investigative Site, Nantes
Novartis Investigative Site, Saint-Herblain
Novartis Investigative Site, Mannheim
Novartis Investigative Site, Heidelberg
Novartis Investigative Site, Lyon
Novartis Investigative Site, Little Rock
Novartis Investigative Site, Houston
Novartis Investigative Site, Freiburg im Breisgau
Novartis Investigative Site, Santa Monica
Novartis Investigative Site, Villejuif
Novartis Investigative Site, Boston
Novartis Investigative Site, Boston
Novartis Investigative Site, Toronto
Novartis Investigative Site, Chiba
Novartis Investigative Site, Tokyo
Novartis Investigative Site, Amsterdam
Novartis Investigative Site, Amsterdam
Novartis Investigative Site, Rotterdam
Novartis Investigative Site, Utrecht
Novartis Investigative Site, Oslo
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Stockholm
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY